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Objectives: Less-invasive options are available for surgical treatment of multivessel
coronary artery disease. We hypothesized that stenting combined with grafting of
the left anterior descending artery with the left internal thoracic artery through a mini-
thoracotomy (hybrid procedure) would provide the best outcome.
Methods: Patients with equivalent numbers of coronary lesions (2.86 0.4) underwent
either hybrid (n5 15) or off-pump coronary artery bypass through a sternotomy (n5
30). Early and 1-year outcomes were compared. Blood drawn from the aorta and cor-
onary sinus immediately postoperatively was analyzed for activation of coagulation
(prothrombin fragment 1.2 and activated Factor XII), myocardial injury (myoglobin),
and inflammation (interleukin 8) by using an enzyme-linked immunosorbent assay.
Target-vessel patency was determined by means of computed tomographic angio-
graphic analysis.
Results: The hybrid procedure was associated with significantly shorter lengths of in-
tubation and stays in the intensive care unit and hospital and perioperative morbidity
(P , .05). Intraoperative costs were increased but postoperative costs were reduced
for the hybrid procedure compared with off-pump coronary artery bypass through
a sternotomy. As a result, overall total costs were not significantly different between
the groups. After adjusting for potential confounders, assignment to the hybrid group
was an independent predictor of shortened time to return to work (t 5 22.12, P 5
.04). Patient satisfaction after the hybrid procedure, as judged on a 6-point scale,
was greater versus that after off-pump coronary artery bypass through a sternotomy.
Finally, the hybrid procedure showed significantly reduced transcardiac gradients of
markers of coagulation, myocardial injury, and inflammation and a trend toward
significant improvement in target-vessel patency.
Conclusions: Perhaps because of reduced myocardial injury, inflammation, and acti-
vation of coagulation, patients undergoing the hybrid procedure had better perioper-
ative outcomes and satisfaction, with excellent patency at 1 year’s follow-up. These
promising preliminary findings warrant further investigation of this procedure.
D
espite major improvements in stent technology, the left internal thoracic ar-
tery (LITA) bypass graft remains the superior long-term option for treating
a stenosis of the left anterior descending coronary artery (LAD).1,2 Compared
with a stent, the LITA graft is resistant to thrombosis and atherosclerosis and provides
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ETAbbreviations and Acronyms
ACT 5 activated clotting time
CABG 5 coronary artery bypass grafting
CAD 5 coronary artery disease
CS 5 coronary sinus
CT 5 computed tomography
ELISA 5 enzyme-linked immunosorbent assay
F1.2 5 prothrombin fragment 1.2
ICU 5 intensive care unit
LAD 5 left anterior descending coronary artery
LITA 5 left internal thoracic artery
MACE 5 major adverse cardiac event
NYHA 5 New York Heart Association
OPCAB 5 off-pump coronary artery bypass grafting
through a sternotomy
PCI 5 percutaneous coronary intervention
SVG 5 saphenous vein graft
protection from progression of proximal coronary artery
disease (CAD). A growing list of less-invasive options has
become available that exploit the benefit of the LITA, includ-
ing off-pump coronary artery bypass grafting (CABG)
through a sternotomy (OPCAB) or multivessel revasculariza-
tion through a small thoratomy.3
A third alternative, percutaneous coronary intervention
(PCI)/stenting combined with surgical LITA to LAD grafting
throughaminithoracotomy (thehybridprocedure), has theoretic
advantages. Stents substitute for the saphenous vein graft (SVG)
as a bypass conduit, and LITA grafting through a minimally in-
vasive approach minimizes surgical morbidity. This hybrid ap-
proach has not been widely adopted because of a number of
practical concerns: the need for close cooperation of surgical
and interventionalgroups, the logistic concerns of timingandse-
quencingof the procedures, and the use of aggressive anticoagu-
lation in the surgical patient.
As a result of these challenges, the status quo for the sur-
gical treatment of multivessel CAD is to perform a sternot-
omy for bypass grafting of a single LITA and multiple
SVGs. At our institution, the surgical and interventional por-
tions of the hybrid procedure have been completed simulta-
neously in a single operative suite. The purpose of this
study was to compare the perioperative and 1-year outcomes
of this state-of-the-art approach to the hybrid procedure
compared with those of standard OPCAB.
Materials and Methods
Patient Selection and Enrollment
Fifteen consecutive patients underwent the simultaneous hybrid pro-
cedure at our institution from January 2005 through December
2006. Using a prospective case-controlled study design, we matched
a parallel control group of 30 patients who underwent OPCAB ac-
cording to demographics, risk factors, comorbidities, coronary anat-
omy, medical therapy, and operative surgeon (RP). These matching
criteria included known risk markers for outcomes with surgical re-368 The Journal of Thoracic and Cardiovascular Surgery c Fevascularization (Table 1). Inclusion criteria for the hybrid procedure
were the presence of multivessel CAD that involved greater than
70% LAD obstruction judged a suitable surgical target and the pres-
ence of a non-LAD coronary lesion (or lesions) suitable for PCI, as
adjudicated by 2 interventionalists (BR and DZ) and 1 surgeon (RP).
Hemodynamic instability, acute coronary syndromes, or situations
in which complete revascularization was not possible served as ex-
clusion criteria for the hybrid procedure. Patients with chronic renal
insufficiency (creatinine value, .2.0 mg/dL) and allergy to radio-
graphic contrast were also excluded from enrollment.
Patients were followed up daily during hospitalization and then
at 1 year as an outpatient to assess mortality, target-vessel patency,
and other outcomes. Demographics, preoperative risk factors and
medications, and intraoperative and postoperative data were pro-
spectively recorded into a relational database. All patients provided
informed consent to be enrolled in the study (UMB IRB no. 25350).
Surgical Procedure
OPCAB. After median sternotomy, the LITA was procured and
the saphenous vein was harvested by using an endoscopic approach
TABLE 1. Patient characteristics
Hybrid procedure
(n 5 15)
OPCAB
(n 5 30) P Value
Age (y) 61 6 10 65 6 10 NS
BMI 29 6 13 27 6 5 NS
COPD 13% 10% NS
Current smoker 27% 33% NS
Diabetes 27% 40% NS
Ejection fraction 47 6 14 45 6 14 NS
Male sex 73% 63% NS
History of familial
coronary artery
disease
33% 40% NS
Hypercholesterolemia 73% 87% NS
Hypertension (.90
and/or.140 mm Hg)
87% 80% NS
No. of diseased vessels 2.7 6 0.5 2.8 6 0.4 NS
NYHA class 2.7 6 1 3.1 6 0.9 NS
Peripheral vascular
disease
33% 27% NS
Previous heart surgery 7% 7% NS
Previous myocardial
infarction
67% 57% NS
Previous stroke 7% 0% NS
Ratio of
revascularized/
diseased vessels
0.93 6 0.14 0.97 6 0.1 NS
Baseline medications
ACE inhibitor 33% 47% NS
Aspirin 93% 87% NS
b-Blocker 100% 80% NS
Intravenous heparin 40% 60% NS
Intravenous nitrates 0% 7% NS
OPCAB, Off-pump coronary artery bypass grafting through a sternotomy;
NS, not significant; BMI, body mass index; COPD, chronic obstructive
pulmonary disease; NYHA, New York Heart Association; ACE, angiotensin-
converting enzyme.bruary 2008
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ET(VasoView6; Guidant Systems, Inc, Minneapolis, Minn). Proximal
anastomoses were performed with a partial occluding aortic clamp.
All distal anastomoses were performed on the beating heart facili-
tated by suction-based exposure and stabilizing devices (Octopus
4.3; Medtronic, Inc, Minneapolis, Minn).
Hybrid procedure. Patients were placed in a supine position
with the left chest slightly elevated and intubated with a double-
lumen endotracheal tube to allow for collapse of the left lung. An
8- to 10-cm anterior lateral thoracotomy in the fourth intercostal
space was created to expose the in situ LITA with the assistance of
the LITA lift retractor (Genzyme Cardiovascular, Cambridge,
Mass). The conduit was then harvested as a pedicle. LITA-to-LAD
CABG was performed through a small thoracotomy without the use
of cardiopulmonary bypass. Selective use of an intracoronary shunt
wasusedbasedonchanges,whichwere suggestive of anteriormyocar-
dial ischemia. A stabilizer (Octopus 4.3; Medtronic, Inc) was then se-
cured over the LAD, and the anastomosis was performed on the
beating heart.Additional targetswere revascularized by usingPCI per-
formed immediately after completion of LITA grafting in a specially
designed operating suite outfitted with fluoroscopic equipment. In
most cases the thorax was closed before PCI. However, for those pa-
tients with higher levels of bleeding, the thorax was left open until
the completion of PCI to allow a second evaluation of hemostasis. Ac-
cesswas achieved through the femoral artery byusing 6Fguiding cath-
eters. Guidewire and stent selection, along with predilation and
postdilation, were left to the discretion of the operator. Drug-eluting
stents were implanted in all patients. Both the Cypher Sirolimus-elut-
ing stent (Cordis Corp, Miami Lakes, Fla) and the Taxus Paclitaxel–
eluting stent (Boston Scientific, Inc, Natick, Mass) were used.
In both groups unfractionated heparin was administered intrao-
peratively to obtain a kaolin-based activated clotting time (ACT)
of greater than 300 seconds and a heparin level of greater than 2
IU/mL, according to the heparin–protamine titration assay (HMS
Heparin Assay Cartridges; Medtronic, Inc). Also, aspirin (325 mg
by mouth daily) was given to both groups preoperatively and within
6 hours postoperatively. Heparin was reversed with half the recom-
mended dose of protamine for OPCAB. For patients undergoing the
hybrid procedure, heparin was not reversed, and a loading dose of
300 mg of clopidogrel was administered through a nasogastric
tube on arrival to the intensive care unit (ICU), followed by 75
mg daily thereafter. GPIIb/IIIa antagonists were not used.
Clinical Outcome and Total Cost Assessment
During hospitalization, major adverse cardiac events (MACEs) were
monitored by determining mortality, perioperative myocardial in-
farction on the basis of new Q-waves or troponin I levels of greater
than 5 times normal values, clinically evident stroke, or the need for
coronary artery reintervention. Intraoperative blood loss was quan-
tified by using a Cell Saver device (Cobe BRAT 2; Cobe Cardiovas-
cular, Arvada, Colo). Chart review was conducted to assess
intraoperative packed red blood cell transfusions, intraoperative
cardiac index and central venous pressure, postoperative length of
intubation, daily serum creatinine level, length of ICU and hospital
stay, and peak pain score (scale, 0–10).
At 1 year after the operation, patients were interviewed, and their
medical records were reviewed to determine the following out-
comes: (1) mortality, (2) MACEs at 1 year, (3) New York Heart As-
sociation (NYHA) angina classification, (4) duration of pain from
surgical incision persisting after the operation, (5) length of timeThe Journal of Thoto return to work or normal activities, and (6) overall satisfaction
with the procedure based semiquantitatively on a score of 1 to 6,
with 1 being dissatisfied and 6 being completely satisfied. Total
costs were obtained for each group by using the hospital’s database.
Regional Hypercoagulability, Myocardial Ischemia,
and Inflammation
Differences in regional hypercoagulability, ischemia, and inflamma-
tion were measured by collecting arterial (‘‘aortic’’) and coronary
sinus (CS) blood samples 30 minutes after heparin reversal into
tubes containing 3.2% citrate. CS blood was obtained through a hep-
arin-bonded catheter (Cook, Inc, Bloomington, Ind) placed into the
CS through transjugular access for patients undergoing the hybrid
procedure or by means of direct external puncture of the CS with
an 18-gauge butterfly needle for patients undergoing OPCAB. Plate-
let-poor plasma was obtained by means of rapid centrifugation
(2000g) and stored at 280C. Thrombin formation was assayed
on the basis of the level of prothrombin fragment 1.2 (F1.2) by
means of enzyme-linked immunosorbent assay (ELISA; Dade Behr-
ing, Marburg, Germany), and the activity of the contact activation
pathway was evaluated by assaying activated Factor XII (American
Diagnostica, Inc, Stamford, Conn). Cardiac myoglobin and interleu-
kin 8 releases were determined by comparing aortic versus CS levels
in the blood samples by means of ELISA (Life Diagnostics, Inc,
West Chester, Pa, and Bender MedSystems, Vienna, Austria, re-
spectively). Comparison of these markers in the CS (F1.2CS) to
a simultaneously obtained aortic (F1.2Ao) sample allowed for calcu-
lation of the percentage of transcardiac change, as follows:
ðF1:2CS2F1:2AoÞ=F1:2Ao3100. Additionally, systemic blood sam-
ples were obtained on postoperative day 1 to assess troponin I levels
by means of ELISA (Life Diagnostics, Inc).
Target-vessel Patency
In addition, target-vessel patency was assessed by using 16-channel
computed tomographic angiography (420-ms rotation with 100–
150 mL of contrast agent administered intravenously at 5 mL/s and
retrospective electrocardiographic gating; Philips MX8000, Cleve-
land, Ohio) at both 5 days (postoperative) and 1 year (follow-up) after
the operation. Patency at both time points was defined as any flow
through the entire graft or stent, regardless of the presence of stenosis.
The graft was classified as nonpatent if a stump was seen or if there
was no contrast in an area knownbyoperative report to contain a graft,
as previously described.4 Thediagnosis of stent thrombosiswasbased
on screening computed tomographic (CT) angiographic analysis,
clinical signs/symptoms of ischemia confirmed as a result of stent
closure by means of conventional angiographic analysis, or both.
Statistical Methods
The primary end point of this trial was a comparison of postopera-
tive morbidity between the 2 groups. We performed univariate anal-
ysis to compare potential confounders of the relationship between
group assignment and time to return to work/normal activities using
the Student t test and the Fisher exact test for continuous and dichot-
omous variables, respectively. Variables with a P value of less than
.1 between groups were included in a stepwise logistic regression
model, with the dependent variable being categorical (time to return
to work of .1 or ,1 month) and independent variables that were
both continuous (age, body mass index, and preoperative creatinineracic and Cardiovascular Surgery c Volume 135, Number 2 369
Evolving Technology Kon et al
ETvalue) and categorical (NYHA classification, diabetes, and number
of diseased vessels). Statistical analyses were performed by a bio-
statistician (AJ).
Results
Baseline patient characteristics were similar between the two
groups in all assessed preoperative and intraoperative
variables (Table 1). All patients received a LITA graft, and
additional targets were addressed per group assignment. The
hybrid group received 22 stents (11 Sirolimus-eluting stents
and 11 Taxus Paclitaxel–eluting stents), and the OPCAB
group received 40 SVGs, 6 right internal thoracic artery
grafts, and 6 radial artery grafts. At 1 year, 80% of patients
in each group successfully completed the follow-up, and
100% returned to assess target-vessel patency.
Early Clinical Outcomes and Hospitalization Costs
There were no mortalities and no readmissions during the
postoperative period in either group. Postoperative MACEs
developed in no patients in the hybrid group and in 7 patients
in the OPCAB group because of 6 myocardial infarctions and
1 stroke (0% vs 23%, P 5 .05). Compared with the OPCAB
group, patients in the hybrid group maintained better intrao-
perative cardiac indices (35% vs 23% decrease from baseline,
P 5 .08) and less of an increase in central venous pressure
(50% vs 17% increase from baseline, P 5 .01). Patients in
the hybrid group also required less red blood cell transfusions
(0.2 6 0.4 vs 1.4 6 1.4 U, P # .0001), shorter intubation
times (1.36 3.4 vs 20.66 25.7 hours, P# .001), and shorter
lengths of stay in the ICU (0.986 0.42 vs 2.426 1.57 days,
P # .0001) and hospital (3.7 6 1.4 vs 6.4 6 2.2 days, P #
.0001). Postoperative renal insufficiency, defined as an in-
crease of serum creatinine values more than 25% above base-
line values, was noted in 3 (10%) patients after OPCAB but
was not seen after the hybrid procedure.
These differences resulted in a significant reduction in
costs for the patients undergoing the hybrid procedure in
the postoperative period. In contrast, OPCAB showed a sig-
nificant reduction in intraoperative costs, largely because of
shorter operative times and the use of autologous grafts rather
than stents ($98196 $2229 vs $14,6916 $2967, OPCAB vs
hybrid procedure; P, .001). As a result of this difference in
intraoperative versus postoperative costs, there was no signif-
icant difference in the overall hospital costs between the
groups (Figure 1). Maximum pain scores, ranging from
none (0) to the most severe ever experienced (10), were
higher after minithoracotomy (hybrid procedure) than ster-
notomy (OPCAB; 8.6 6 1.8 vs 6.8 6 2.7, P 5 .01).
As the result of different protocols for heparin reversal,
there was a significant difference in the ACT measured
immediately at the completion of the case for patients in the
hybrid group compared with those in the OPCAB group
(235 6 56 vs 132 6 23 seconds, P , .001).370 The Journal of Thoracic and Cardiovascular Surgery c FebOne-year Outcomes
At 1 year’s follow-up, there was no mortality in either group.
MACEs were noted in 1 (7%) of the patients in the hybrid
group and in 7 (23%) of the patients in the OPCAB group
as a result of 1 reintervention required for a patient in the hy-
brid group for stent thrombosis. This patient was also the only
patient in either group with angina at 1 year (mean NYHA an-
gina classification: 0.2 vs 0, hybrid procedure vs OPCAB).
The duration of the time that it took for pain to completely
resolve was shorter for the hybrid procedure versus OPCAB
(10.3 6 10.9 vs 45.5 6 33.6 days, P 5 .004). Overall satis-
faction scores were also higher after the hybrid procedure
(Figure 2), with significantly more patients reporting that
they were completely satisfied (83% vs 42%, hybrid proce-
dure vs OPCAB; P , .001).
Patients returned to work or normal activities quicker after
the hybrid procedure versus OPCAB (Figure 3). The average
time to return to work in patients with a sternotomywas 4.46
3.1 months, which is significantly greater than the 1.756 1.0
months for patients with a minithoracotomy (t 5 3.68, P 5
.0008). Therewas a significant relationship between group as-
signment (ie, hybrid vsOPCAB) and returning towork before
1month (c2 statistic5 7.08, P5 .008). The odds of returning
to work at less than 1 month were significantly better for the
hybrid procedure versus OPCAB after adjusting for potential
confounders (odds ratio, 7.60; 95% confidence interval, 1.61–
35.91; P 5 .01). On multivariate regression analysis, the
choice of procedure was a significant predictor of the time
Figure 1. Although a significant increase in operative costs was
noted in the hybrid group (P<.001), total averagecostswerenot sig-
nificantly different between thegroups. Thiswas the result of signif-
icantly lower postoperative costs (P<.001) in the hybrid group,with
its reduction in transfusions and lengths of intensive care unit and
hospital stay versus the off-pump coronary artery bypass grafting
through a sternotomy (OPCAB) group. NS, Not significant.ruary 2008
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95% confidence interval,24.04 to20.11). None of the other
variables analyzed were significant predictors.
Regional Hypercoagulability, Myocardial Ischemia,
and Inflammation
There was significantly less intraoperative blood loss during
the hybrid procedure versus OPCAB (5796 406 vs 10916
Figure 2. At 1 year, patients reported their overall satisfaction
with the procedure on a 1- to 6-point scale, ranging from dissatis-
fied to completely satisfied. The hybrid group reported a signifi-
cantly higher mean level of satisfaction compared with that of
the off-pump coronary artery bypass grafting through a sternotomy
(OPCAB) group, with 83% of patients in the hybrid group versus
42% of patients in the OPCAB group completely satisfied (P #
.001, Fisher exact test).
Figure 3. The time for each patient to return to work (or normal ac-
tivity for those who do not work) was monitored in each patient
group. The period required for patients in the hybrid group was
significantly shorter compared with that of the off-pump coronary
artery bypass grafting through a sternotomy (OPCAB) group. After
adjusting for potential confounders with a multivariate analysis,
assignment to the hybrid group was found to be an independent
predictor of a shorter length of time to return to work/normal
activities (t 5 22.5, P 5 .02).The Journal of Tho601 mL, P 5 .004). Despite better hemostasis, the transcar-
diac gradients of markers of thrombosis (F1.2 and activated
Factor XII), ischemia (myoglobin), and inflammation (inter-
leukin 8) were all significantly reduced after the hybrid pro-
cedure versus OPCAB (Figure 4). Troponin I levels on day 1
were significantly less in patients undergoing the hybrid
procedure versus those undergoing OPCAB (1.4 6 0.7 vs
2.8 6 2.6 ng/mL, P , .03).
CTAngiographic Follow-up
Conventional angiography performed during each case intra-
operatively and CT angiography performed before hospital
discharge confirmed target-vessel patency for all patients in
the hybrid group. Predischarge CT angiographic results
obtained in the OPCAB group documented patency in 77
(94%) of 82 grafts, with early failure noted in 1 right internal
thoracic artery graft, 1 radial artery graft, and 3 SVGs. At
1 year, a single stent failed in the hybrid group versus 7
additional SVG failures in the OPCAB group (97% vs 85%
overall patency, Figure 5).
Discussion
OPCAB was initially touted as a less-invasive alternative to
the traditional on-pump technique, yet direct comparisons
of outcomes between these methods have been surprisingly
similar. The hybrid procedure has been established in prior
reports as a viable alternative to open-sternum CABG for se-
lected patients with multivessel disease.5-7 We performed
Figure 4. Myocardial ischemia, inflammation, and activation of
coagulation were analyzed within the heart after hybrid versus
off-pump coronary artery bypass grafting through a sternotomy
(OPCAB) procedures by obtaining aortic and coronary sinus blood
samples 30 minutes after case completion. The transcardiac gra-
dients of serum levels of markers of thrombin formation (prothrom-
bin fragment 1.2 [F1.2]), activation of the intrinsic coagulation
cascade (activated Factor XII [FXII-a]), ischemia (myoglobin),
and inflammation (interleukin 8 [IL-8]) were all significantly
reduced after the hybrid procedure versus OPCAB.racic and Cardiovascular Surgery c Volume 135, Number 2 371
Evolving Technology Kon et al
ETstenting and bypass simultaneously using a specially outfitted
hybrid operating suite at our center. A variety of better out-
comes were noted in patients treated with this state-of-the-
art approach compared with OPCAB, including reduced
lengths of intubation and ICU stay, less transfusions, quicker
resolution of pain, earlier return to work/normal activities,
and greater overall satisfaction with the surgical experience.
Although target-vessel patency at 1 year’s follow-up was ex-
cellent in both groups, cardiac release of hypercoagulability
markers was reduced after the hybrid procedure, suggesting
a decreased risk for coronary thrombotic events in these pa-
tients. Our experience suggests that an encouraging array
of advantages might follow the adoption of a less-traumatic
technique, such as the hybrid procedure, that have not yet
materialized by merely avoiding cardiopulmonary bypass.
Finding reduced postoperative costs for our hybrid group
was notable given that OPCAB represents the best available
evidence-based approach for cost savings.8,9 It is possible
that enthusiasm for the hybrid procedure biased the manage-
ment of variables that are often based on subjective judg-
ments and also are important drivers of hospital costs, such
as time for extubation, length of stay, and red blood cell trans-
fusion. We believe the risk of this type of bias was minimized
by the fact that our study was performed in the context of de-
creasing reimbursements for CABG, which creates a strong
incentive to limit costs regardless of the approach. The differ-
ences in postoperative costs were offset by higher intraoper-
ative costs for the hybrid procedure because of longer
operative times and the costs of coated stents. Further reduc-
tions in operative times because of the learning curve of min-
Figure 5. An analysis of early graft and stent patency was ob-
tained by using multichannel computed tomographic angiography
before discharge and again at 1 year. This analysis showed a trend
toward better midterm target-vessel patency for the hybrid group.
Both groups received 100% follow-up at both time points. OPCAB,
Off-pump coronary artery bypass grafting through a sternotomy;
NS, not significant.372 The Journal of Thoracic and Cardiovascular Surgery c Febimally invasive surgery and the recent transition to less-costly
bare-metal stents to avoid delayed thrombosis might help
improve total costs in our ongoing analysis.
Despite higher pain scores after minithoracotomy versus
sternotomy, the odds of patients in the hybrid group returning
to work within the first month were 7-fold better than that of
patients in the OPCAB group, even after adjusting for poten-
tial confounders. Multivariate techniques cannot adjust for all
the factors that influence a subjective end point such as the
appropriate time to return to work. Although not detected
in interviews, patients, their providers, or both could have
had the preconceived notion that the hybrid procedure is
more likely than OPCAB to allow a quicker return to nor-
malcy. However, early return to work was the stated goal
of a vast majority of the patients in this cohort. Recovery
time defined in this broader context provides an important
benchmark for programmatic success from the standpoint
of the patient and helps to justify the use of a strategy that
is not the standard of care for triple-vessel CAD.
More rapid recovery for the hybrid cohort suggests that fac-
tors other than pain play a role in their quicker recovery. Less
blood transfusions and reduced systemic inflammation have
been linked to improved postoperative morbidity in a number
of studies comparing minimally invasive and conventional
surgery and likely play a role in outcomes after the hybrid pro-
cedure. In addition, the degree of cardiac manipulation varies
between the hybrid procedure, where the heart is left in its na-
tive position, versus OPCAB, which frequently requires the
heart to be rotated into positions that compromise hemody-
namics, as noted in our patients. In addition, coronary occlu-
sion for the hybrid procedure is limited to that required for
placement of a single LADgraft and less than 20-second inter-
vals for stenting. OPCAB requires 8- to 12-minute periods of
coronary occlusion during each of 3 to 4 distal anastomoses
(total ischemic time, 25–40 minutes). Better myocardial pro-
tection, reflected by a reduction in regional myoglobin and
systemic troponin I release,might be an additionalmechanism
for quicker recovery after the hybrid procedure.
Compared with those undergoing OPCAB, patients un-
dergoing the hybrid procedure showed a reduced transcardiac
gradient of F1.2, a marker of thrombin production. This
methodology has been used to assess coagulation activity
within the upstream coronary circulation in a wide range of
clinical studies.10-12 F1.2 is a proved risk factor for thrombo-
sis of stents13 or bypass grafts14 and predicts morbidity after
cardiac surgery. Potential triggers for thrombin in patients
undergoing OPCAB are the obligatory periods of warm
ischemia15 or the grafting of the more thrombogenic SVG
versus using all arterial conduits.16 Additionally, reversal
of heparin with protamine, avoided in the hybrid group, is
known to provoke a transient ‘‘rebound’’ increase in throm-
bin formation. As evidenced by a significant difference in
postoperative ACT, the heparin effect resolved in the patients
undergoing the hybrid procedure after the time point at whichruary 2008
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flect changes in the kinetics of thrombin formation and not
just a determination of the relative thrombogenicity of each
procedure. On the other hand, the safe use of more aggressive
antithrombotic therapies, such as heparin administration
without reversal, is the result of less risk of bleeding after
the hybrid procedure. Undoubtedly, there are a variety of fac-
tors that influence the calculus of regional thrombin produc-
tion after surgical revascularization.
A final advantage of the hybrid procedure is that it pro-
vides surgical revascularization without requiring an SVG.
Although our study was not sufficiently powered to docu-
ment a difference in target-vessel patency between groups,
the use of the SVG is well known to limit the longevity of sur-
gical treatment for multivessel CAD. All arterial grafting pro-
vides a theoretic advantage over the hybrid procedure by
avoiding patient exposure to the potential risks of intracoro-
nary restenosis, thrombosis, or both from either stents or
SVGs. However, all-arterial grafting has not been enthusias-
tically adopted by most cardiac surgeons, in part because the
best choice for arterial conduits after the LITA remains con-
troversial. The right internal thoracic artery has shown excel-
lent patency rates and increased survival advantage17-19 but is
not often used because of the fear of sternal infection and a va-
riety of other technical considerations.20,21 The radial artery
is a versatile arterial conduit accustomed to pulsatile pressure
but has demonstrated highly variable early patency results,
preventing a consensus about its role in CABG.22,23 As a re-
sult, a recent review of the Society of Thoracic Surgeons da-
tabase indicates that 95% of CABG cases nationwide involve
an SVG. Therefore, the hybrid procedure might be a more
practical solution for avoiding the well-known limitations
of the SVG than all-arterial grafting.
Limitations
This pilot study has limitations that need to be considered
when interpreting the data. First, patient assignment to
groups was nonrandomized. Although this could serve to
bias the selection of lower-risk patients for the minimally in-
vasive approach, our hybrid cohort had a higher incidence of
chronic obstructive pulmonary disease, peripheral vascular
disease, and prior myocardial infarction and stroke compared
with the OPCAB control group.
Second, subjective measures, such as the patient’s satis-
faction and time to return to work, could have been influ-
enced by preconceived notions about the superiority of the
hybrid approach. However, randomization is not able to blind
the patient to whether a minithoracotomy for the hybrid pro-
cedure or sternotomy for OPCAB was performed. The risk of
this bias can only be controlled by comparing the hybrid
group with one that is revascularized with multiple arterial
grafts through a minithoracotomy.
Third, comparison of target-vessel patency between
groups over the first postoperative year might not be suffi-The Journal of Thocient to demonstrate the longevity advantages of bypass
grafting over PCI that typically become evident only after 3
to 5 years of follow-up. These data provide reassurance, how-
ever, that the technical success of LAD grafting does not
appear to be compromised by using a minimally invasive
approach.
Finally, hybrid operating rooms with permanent fluoro-
scopic equipment are currently available at only a few
centers, limiting the generalizability of our protocol. Our re-
sults cannot be extrapolated to the hybrid procedure per-
formed as a staged procedure. Proliferation of percutaneous
procedures for vascular stenting and valvular disease might
make rooms for the simultaneous hybrid procedure more
common in the future. Although our data support the feasibil-
ity of the hybrid approach, it is best interpreted as hypothesis
generating to support the design of more appropriately
powered, randomized studies in the future.
Conclusions
In conclusion, the treatment of multivessel CAD with the si-
multaneous hybrid approach provides a rapid recovery and
a level of patient satisfaction that compares favorably with
that of traditional OPCAB. These results were seen without
significantly increasing costs or compromising graft patency.
In addition, local activation of inflammation and coagulation
was minimized by the hybrid procedure, perhaps because of
reduced myocardial manipulation and warm ischemia. These
promising early findings warrant further investigation of the
simultaneous hybrid procedure.
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Discussion
Dr Marc Ruel (Ottawa, Ontario, Canada). I enjoyed your presen-
tation. I regularly perform MVST as well. I think it is a great oper-
ation. I wanted to ask you a couple of technical questions about this
operation.
First, I see that most of your patients underwent 2-vessel revas-
cularization. As you know, it is possible to do complete triple-vessel
revascularization. With regard to that, how often do you bypass the
right artery or its branches, and if you do a 3-vessel revasculariza-
tion, what is your conduit selection strategy?374 The Journal of Thoracic and Cardiovascular Surgery c FebDr Kon. Thank you. I am going to defer this question to my
primary investigator.
Dr Poston. I am Robert Poston, senior author of the study and
the one who did these procedures. The question of whether we in-
completely revascularized our patients who underwent a minimally
invasive approach is important. We do not want to emphasize the
use of minithoracotomy and having the patient leave the hospital
sooner more than performing an effective operation. As shown in
the slide, we actually had 2.5 diseased vessels in the MVST group,
the hybrid group had 2.7, and our standard OPCAB total is 2.8. I
agree with you that these patients had less total disease than you
might see with a typical CABG referral that requires 3- or 4-vessel
grafting. However, the minimally invasive and sternotomy groups
were fairly comparable in terms of their disease. In addition, the ratio
of the number of diseased to the number of revascularized vessels
was also similar between groups, with only a slight reduction in
the MVST group at 0.88, which was not likely to be clinically
significant.
The most compelling case about choosing the minimally inva-
sive surgery approach is the use of arterial grafts and avoiding the
limitations of the vein grafts that are used in 95% of sternotomy
cases. We know that vein grafts are going to fail at a higher rate
both at the early time point and at rates of up to 30% at 1 year, as
evidenced by the recently published PREVENT IV trial.
Dr Valavanur Subramanian (New York, NY). We presented our
multivessel/small vessel thoracotomy for multiple coronary artery
bypass, paving the way for outpatient surgery. Our length of stay
was actually very good—less than 3 days in the majority of the
patients—and about 50% went home 14 hours after the operation.
Therefore my question is this: If you are able to perform multiple
arterial grafting through theMVST approach, why the hybrid proce-
dure, except for the right coronary artery?
Dr Kon. A lot of that has to do with the right coronary artery.
You are limited to the lateral anterior surface of the heart, whereas
the hybrid procedure allows you to really revascularize right-sided
lesions.
Dr Poston. I would echo that. It is just technically much more
straightforward to put a stent in a vessel going to the posterior heart
than to try to graft that. Therefore that was always our first choice,
particularly with the use of a coated stent that is going to perform
quite well in the long term compared with a vein graft. A case can
be made that the stent might exceed the results of even the radial
artery graft because you do not have to deal with conduit spasm,
an issue that has not completely been resolved with the radial artery.
There might even be an increased propensity to spasm when the ra-
dial artery is used as a Y graft, which is the rule for minimally inva-
sive cases. Therefore if we had a good candidate with a stentable
right or circumflex artery, but particularly for the right coronary
artery, as you suggested, then the hybrid procedure was the first
choice for our minimally invasive program.
DrMichael A. Acker (Philadelphia, Pa). Rob, with the new in-
formation about the drug-eluting stents, do you still feel that way?
When you put a drug-eluting stent in now, it is really an issue for
life. You have all seen these acute thromboses, and it is now being
recognized, even by the cardiology community, where the pendu-
lum is swinging, because now they want to put in the bare-metal
stents. They are nervous about the drug-eluting stents.ruary 2008
Kon et al Evolving TechnologyDr Poston. It depends on the quality of the target. If you are put-
ting coated stents into small coronary arteries, then that thrombosis
issue is going to be real, but if you put it into a large proximal vessel
of 3.0 mm in diameter, then it would seem that the risk of thrombosis
is going to be pretty low. According to the US Food and Drug Ad-
ministration’s preliminary analysis, the thrombosis issue is largely
related to pushing the envelope with off-label use of stents and prob-
ably not so much with the on-label use in the large coronary targets.
Dr Ralph J. Damiano (St Louis, Mo). Congratulations on your
very nice presentation. You just touched briefly on the economics of
this approach. First, I would tell you that length of stay in a non-
blinded study is extremely subjective, and I would not put much em-
phasis on those data. Saving one day in the hospital really saves you
little. Most of the cost of coronary surgery is incurred in the operat-
ing room and in the first 24 hours.
I would wonder whether you have done an economic analysis be-
cause your approach, I think, is expensive and is another reason
probably not to adopt this as opposed to just doing MVST or an OP-
CAB. Have you looked at the cost of this, including the cost of your
coated stent, and then have you looked at the cost of having to stay
on clopidogrel for a full year, which I am sure you tell your patients
to do. Basically, in most hospitals you have eliminated any possibil-
ity for any elective surgery for the next year. Therefore after a year of
including the clopidogrel cost in your hybrid group compared with
your other groups, could you describe the difference in the health
care economics of these approaches?
DrKon. Thank you very much for that question. In fact, we did
do a cost analysis because we were worried that the additional cost
of these stents would be significant. However, primarily becauseThe Journal of Thothe patients stayed in the hospital a shorter period of time and
ICU time and blood transfusions were reduced, we did not see
a significant increase in costs between the hybrid procedure and
OPCAB groups.
As far as clopidogrel use over 1 year, I cannot give you numbers,
but definitely in the short term total cost of the procedure and postop-
erative hospital carewas equivalent betweengroups,with only aminor
increase, which was not statistically significant, in the hybrid group.
DrMichael Mack (Dallas, Tex). Dr Kon, let me ask you 2 ques-
tions. I assume that these patients were not randomized, and if not,
why not?
Dr Kon. Traditionally, patients with 2- or 3-vessel disease in our
institution underwent a standard OPCAB sternotomy. We recently
began a minimally invasive program in which we wanted to effec-
tively do a pilot study just to see how efficacious these procedures
were, and after these findings, we certainly hope to attempt a larger
randomized trial to confirm these results.
DrMack. Threeofyour4 endpoints arevery caregiver driven: time
to extubation, ICU stay, and length of hospital stay. Were these all pro-
tocol-driven management issues because there is a wide variability in
anesthesiologists and preference for extubation and things like that?
Dr Kon. It is true that specifically hospital stay and perhaps even
ICU stay are very subjective as far as the caregiver’s decisions of
when to allow a patient to leave or to advise a patient to leave, but
that is why we specifically followed up with more objective analyses
that were not biased by the perception of the caregiver, such as inci-
sional pain time and time to return to work and overall satisfaction.
The actual decision to leave the ICU or hospital was based on
physician preference.racic and Cardiovascular Surgery c Volume 135, Number 2 375
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